Nordea Investment Management AB Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Nordea Investment Management AB lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 6.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 46,988 shares of the biopharmaceutical company’s stock after purchasing an additional 2,768 shares during the quarter. Nordea Investment Management AB’s holdings in Regeneron Pharmaceuticals were worth $24,521,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Marietta Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 30.2% in the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company’s stock worth $6,836,000 after purchasing an additional 2,501 shares in the last quarter. Sepio Capital LP boosted its holdings in shares of Regeneron Pharmaceuticals by 33.1% in the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company’s stock worth $2,150,000 after purchasing an additional 842 shares in the last quarter. Founders Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 7.0% in the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company’s stock worth $4,344,000 after purchasing an additional 538 shares in the last quarter. PGGM Investments boosted its holdings in shares of Regeneron Pharmaceuticals by 159.7% in the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company’s stock worth $44,308,000 after purchasing an additional 51,900 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company’s stock valued at $16,255,000 after acquiring an additional 955 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on REGN shares. Wells Fargo & Company cut Regeneron Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $580.00 target price for the company. in a report on Friday, August 1st. Guggenheim increased their target price on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a report on Friday, August 1st. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Truist Financial dropped their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a report on Monday, August 11th. Finally, Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a “sector perform” rating in a report on Monday, August 4th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $817.88.

Regeneron Pharmaceuticals Trading Up 1.6%

REGN opened at $578.05 on Friday. The business has a 50 day simple moving average of $574.64 and a two-hundred day simple moving average of $562.46. The firm has a market capitalization of $61.27 billion, a price-to-earnings ratio of 14.57, a PEG ratio of 1.80 and a beta of 0.31. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,002.69.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $11.56 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.